Emcure Pharmaceuticals IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Last Updated Date: Jul 07, 2024Let’s have a detailed review of the company and analytics of the Emcure Pharmaceuticals IPO release date, IPO offer price, subscription, Emcure Pharmaceuticals Limited IPO allotment, grey market price, and other Emcure Pharma IPO details like the company’s background, its financial positions, its promoters, and other related things.
| Face Value | Rs 10 |
| Price Band | Rs 960 to Rs 1008 |
| Listing At | BSE, NSE |
| Min. Order Quantity | 14 Shares |
| Listing Date | July 10, 2024 |
| Offer for Sale | Rs 1,152.03 Cr. |
| Fresh Issue | Rs 800.00 Cr. |
| IPO Size | Rs 1,952.03 Cr. |
| Tick Size | 1 |
Emcure Pharmaceuticals IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.
Emcure Pharmaceuticals IPO – Summary
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
They are an R&D-driven company with a differentiated product portfolio that includes orals, injectables, and biologics, as well as an mRNA platform through which they are currently developing a COVID-19 vaccine.
The Promoter of this company is : SATISH RAMANLAL MEHTA, SUNIL RAJANIKANT MEHTA, NAMITA VIKAS THAPAR AND SAMIT SATISH MEHTA. The lead managers to the issue are Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited and J.P. Morgan India Private Limited, and the Registrar to this issue is Link Intime India Private Limited.
Emcure Pharmaceuticals IPO Date
The opening and the closing date of Emcure Pharmaceuticals IPO are July 3, 2024and July 5, 2024, respectively.
Check out Related IPO Links:
| Emcure Pharmaceuticals IPO GMP |
| Allotment – Emcure Pharmaceuticals IPO |
Emcure Pharmaceuticals IPO Subscription
| Day / Date | QIB | NII | RII | Emp | Total Subscription |
| 1st Day – 3rd Jul | 0.07x | 2.78x | 1.46x | 2.34x | 1.34x |
| 2nd Day – 4th Jul | 0.97x | 13.99x | 3.55x | 4.92x | 5.01x |
| 3rd Day – 5th Jul | 191.24x | 49.32x | 7.36x | 8.81x | 67.87x |
| Shares Offered or Net Issue | 3,853,234 | 2,889,926 | 6,743,160 | 108,900 | 19,483,388 |
The shares subscribed by the public will be updated here.
Check Emcure Pharmaceuticals IPO LIVE Subscription
- Emcure Pharmaceuticals IPO LIVE Bid details on BSE
- Emcure Pharmaceuticals IPO LIVE Bid details on NSE
For the Latest Bid details click on the above links.
Emcure Pharmaceuticals IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.
Emcure Pharmaceuticals Limited IPO Listing Date
Find the dates below on basis of allotment, refund, listing, and more:
| Basis of Allotment Finalization | July 8, 2024 |
| Refunds Initiation | July 9, 2024 |
| Credit of Shares to Demat Account | July 9, 2024 |
| Share Listing Date | July 10, 2024 |
Emcure Pharmaceuticals IPO Price Band
The face value of each share is Rs.10, but the price band of the IPO is Rs 960 to Rs 1008
Emcure Pharmaceuticals IPO Equity Size
This Initial Public Issue of 19,365,346 Equity Shares of Rs.10 each for cash at a price of Rs 960 to Rs 1008 per equity share aggregating to Rs.1,952.03 Cr.
Emcure Pharmaceuticals IPO Share Offering
Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of 7,936,507 Equity Shares of Rs.10/ each.
Issue Size: 19,365,346 Equity Shares of Rs.10 each, aggregating to Rs.1,952.03 Cr.
Open Free Demat Account Now!
Emcure Pharmaceuticals IPO – Live Performance
The listing date of this IPO is July 10, 2024. You can check the live performance of the IPO here, only after it is listed on exchanges.
| Live IPO Performance – Emcure Pharmaceuticals Share Price |
Emcure Pharmaceuticals IPO Grey Market Premium
The Emcure Pharmaceuticals Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X.
Emcure Pharmaceuticals IPO – Company Overview
They have experienced rapid growth in recent years and, according to CRISIL, they are one of the fastest-growing pharmaceutical companies in India as measured by the increase in their sales of pharmaceutical products in India.
They believe that their competitive advantage in the domestic market stems from their established presence in most of the major therapeutic areas, including, gynaecology, cardiovascular, vitamins, minerals and nutrients, oncology/antineoplastic, HIV, and blood-related.
Across all such therapeutic areas, they were ranked among the top 10 pharmaceutical companies in India in terms of sales in India in the Financial Year 2021, according to CRISIL.
Their portfolio is focused towards pharmaceutical products used in chronic (including sub-chronic) therapeutic areas, which they believe are therapeutic areas with the highest growth potential in India.
Emcure Pharmaceuticals IPO – Financial Statements
A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:
Financial Summary:
| Amount (in INR & Million) | |||
| 31-Mar-24 | 31-Mar-23 | Mar-22 | |
| Total Assets |
78,061.63
|
66,725.31
|
60,634.69
|
| *Total Revenue |
67,152.41
|
60,317.16
|
59,188.60
|
| Total Expense |
59,780.82
|
52,783.55
|
49,463.12
|
| Profit After Tax |
5,275.75
|
5,618.45
|
7,025.56
|
Earnings per Equity Share (in Million)
| 31-Mar-24 | 31-Mar-23 | Mar-22 | |
| Basic & Diluted |
27.54
|
29.42
|
36.62
|
Further, their PAT for the period ended on March 31, 2024, March 31, 2023, and March 31, 2022, were Rs. 5,275.75 Million, Rs. 5,618.45 Million and Rs. 7,025.56 Million respectively.
Emcure Pharmaceuticals IPO – Promoters
The Promoter of this company is:
- SATISH RAMANLAL MEHTA,
- SUNIL RAJANIKANT MEHTA,
- NAMITA VIKAS THAPAR
- SAMIT SATISH MEHTA
List of Related Parties (Key Managerial Personnel)
- Berjis Desai, Chairman, and Independent Director
- Satish Mehta, Managing Director, and Chief Executive Officer
- Sunil Mehta, Whole-time Director
- Namita Thapar, Whole-time Director
- Mukund Gurjar, Whole-time Director
- Shreekant Bapat, Independent Director
Emcure Pharmaceuticals IPO – Promoters Holding
- Pre Issue Share Holding – 98.90%
- Post Issue Share Holding – %
Emcure Pharmaceuticals IPO Offer Details or Issue Details
| Particulars | No. Of Equity Shares |
| Equity Shares Offered | Up to X Equity Shares aggregating up to Rs.1,952.03 Cr. |
| of which: | |
| Issue Reserved for the Market Makers | Up to [●] Equity Shares aggregating up to Rs.[●] Million |
| Net Issue to the Public | Up to [●] Equity Shares aggregating up to Rs.[●] Million |
| Of which: | |
| Retail Investors Portion | Not less than [●] Equity Shares |
| Other than Retail Individual Investors | Not more than [●] Equity Shares |
| Equity Shares outstanding prior to the Issue | 180,852,116 Equity Shares |
| Equity Shares outstanding after the Issue | X Equity Shares |
Emcure Pharmaceuticals IPO Issue Object
Their Company proposes to utilize the Net Proceeds towards funding the following objects:
1. Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by their Company; and
2. General corporate purposes
Emcure Pharmaceuticals IPO – Business Strategy
- Increase Their Market Share in the Domestic Market
- Invest in R&D and Manufacturing Capabilities to Enhance and Grow their Differentiated Product Portfolio
- Deepen and Expand Their International Presence with a Focused Go-to-Market Approach
- Pursue Strategic Acquisitions, Partnerships and In-Licensing
Emcure Pharmaceuticals IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Well-placed to leverage their position in the domestic market.
- Demonstrated capabilities of building brands.
- Large, diversified and fast-growing product portfolio in international markets.
- Strong R&D capabilities driving a differentiated portfolio of products.
- Extensive and diversified manufacturing capacity.
- Highly qualified, experienced and entrepreneurial management team and Board.
The relevant quantitative factors are:
| Basic & Diluted EPS | RONW (%) | NAV (Rs.) | |
| 31-Mar-24 |
27.54
|
16.87
|
163.22
|
| 31-Mar-23 |
29.42
|
21.27
|
– |
| Mar-22 |
36.62
|
33.32
|
– |
Emcure Pharmaceuticals IPO: Competitive Peers
| Face Value (Rs.) | P/E | EPS (Rs.) | Return on Net Worth (%) | Revenue from operations (Rs. in Millions) | |
| Emcure Pharmaceuticals Limited | 10 | [●] |
27.54
|
16.87
|
66,582.51
|
| Listed Peers | |||||
| Dr. Reddy’s Laboratories Limited | 5 |
17.93
|
335.22
|
19.74
|
280,111.00
|
| Cipla Limited | 2 |
30.10
|
51.05
|
15.43
|
257,740.90
|
Emcure Pharmaceuticals IPO Lead Managers
| Lead Managers |
|
Kotak Mahindra Capital Company Limited Axis Capital Limited Jefferies India Private Limited J.P. Morgan India Private Limited |
Emcure Pharmaceuticals IPO Registrar to offer
| Registrar to the Offer |
| Link Intime India Private Limited C-101, 1st Floor, 247 ParkLal Bahadur Shastri Marg, Vikhroli (West) Mumbai 400 083 Maharashtra, India Tel:+ 91 810 811 4949 Email:emcure.ipo@linkintime.co.in Website:www.linkintime.co.in Investor grievance e-mail:emcure.ipo@linkintime.co.in Contact Person: Shanti Gopalkrishnan SEBI Registration No.:INR000004058 |
Emcure Pharmaceuticals IPO – Other Details
- Statutory Auditor – B S R & Co. LLP, Chartered Accountants
- Legal Counsel to the Company – AZB & Partners
- Bankers to the Company – Axis Bank Limited, Bank of Maharashtra, Bank of Baroda, Export-Import Bank of India, HDFC Bank Limited, Standard Chartered Bank, and State Bank of India
Emcure Pharmaceuticals IPO Review by Stock Brokers
| Top Stock Brokers Review | Company Reputation | Competitive Edge | Financial Statement | Popularity Index | Promoters Reputation |
| Angel Broking | 7.5/10 | 7.4/10 | 8.5/10 | 8.1/10 | 7.1/10 |
| Sharekhan | 7.2/10 | 7.1/10 | 8.6/10 | 8.1/10 | 7.2/10 |
| Kotak Securities | 7.3/10 | 7.5/10 | 8.4/10 | 8.1/10 | 7.3/10 |
| ICICI Direct | 7.3/10 | 7.3/10 | 8.7/10 | 8.1/10 | 7.1/10 |
| IIFL | 7.5/10 | 7.2/10 | 8.8/10 | 8.0/10 | 7.1/10 |
| Edelweiss | 7.5/10 | 7.4/10 | 8.4/10 | 8.3/10 | 7.2/10 |
| Zerodha | 7.4/10 | 7.1/10 | 8.5/10 | 8.1/10 | 7.0/10 |
| 5Paisa | 7.1/10 | 7.1/10 | 8.4/10 | 8.1/10 | 7.1/10 |
| Karvy | 7.4/10 | 7.3/10 | 8.2/10 | 8.1/10 | 7.1/10 |
| Motilal Oswal | 7.1/10 | 7.1/10 | 8.6/10 | 8.3/10 | 7.2/10 |
Subscribe to Emcure Pharmaceuticals IPO
Emcure Pharmaceuticals Limited IPO News
News 1 – IPO DRHP Download
News 2 – IPO RHP Prospectus Download
Emcure Pharmaceuticals IPO Review FAQs
What is the Issue Size of Emcure Pharmaceuticals IPO?
The Company is making an initial public offer of 19,365,346 equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.
What is the Price band of Emcure Pharmaceuticals IPO?
The price band for this particular IPO ranges between Rs 960 to Rs 1008. As far as the face value of the share is concerned, it is Rs.10 per share.
What is the Emcure Pharmaceuticals IPO Open Date?
The opening and closing dates for this IPO have been updated. The IPO is set to open on July 3, 2024, while the closing date is set at July 5, 2024.
What is the Emcure Pharmaceuticals IPO Allotment Date?
They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on July 8, 2024, refund initiation is on July 9, 2024, credit of shares is on July 9, 2024, and share listing date is on July 10, 2024.
What is the Emcure Pharmaceuticals IPO Listing Date?
Shares of this company shall be listed in the exchanges on July 10, 2024. The date, when the listing would be done, is stagnant on July 10, 2024.
Who is the Registrar of Emcure Pharmaceuticals IPO?
One of the reputed registrars is managing the issue of this IPO, i.e. Link Intime India Private Limited. Their website will help you regarding the further information you are on the lookout for.
Who is the Promoter of Emcure Pharmaceuticals IPO?
Here are the promoters of this IPO – SATISH RAMANLAL MEHTA, SUNIL RAJANIKANT MEHTA, NAMITA VIKAS THAPAR AND SAMIT SATISH MEHTA. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
What is the GMP of Emcure Pharmaceuticals IPO?
They have obtained the GMP of this IPO and it is NA. Further insights into the Kostak rate and subject to sauda or SS are also included in this report.
Is Emcure Pharmaceuticals IPO Good for Investment?
They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
What is the PAT of Emcure Pharmaceuticals Company?
They have the information on company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2024 in Million is 5,275.75, 2023 is 5,618.45, 2022 is 7,025.56.
Calculate your return on investment!
Asset Class
ROI (Rs.)
Profit (Rs.)
Profit (%)
IPO
Equity
Savings
Real Estate
Gold
Bonds
Fixed Deposit
Mutual Fund
Featured Topics